课题基金 / 基金详情

项目摘要

项目成果

Andrew John Norris的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): In a screen for naturally occurring angiogenic inhibitors, we have identified an extract from the plant Livistona chinensis, which has potent anti-angiogenic and anti-tumor activity and is non-toxic in mice. To our knowledge, ours is the first publication in the English literature on this extract from Livistona chinensis. We hypothesize that the Livistona extract inhibits tumorigenesis and angiogenesis, and that the effects exerted by many one or more active components in Livistona chinensis may be critical to the chemopreventive or chemotherapeutic application of this extract. In this innovative research proposal, we will identify the active ingredient(s) in the extract based on the in vitro anti-proliferative and antiangiogenic assays; investigate whether these components have an effect when used in in-vivo testing. Our specific aims for Phase 1 are as follows: Aim 1: To isolate and identify the active component(s) from the plant Livistona chinensis using a variety of chemical and analytical techniques, including extraction, chromatographic separation, nuclear magnetic resonance, photo diode array, infrared and high resolution mass spectrometry. Aim 2: To test the effect of cach active component on in vitro breast tumorigenicity and antiogenesis assays. The active components will be tested in breast tumor xenograft models. Furthermore, we will begin to investigate the mechanism(s) of action exerted by the active compound(s). Considering the observed low toxicity, oral availability, stability, and potent pharmacologic activity in our animal models from the plant extract, we see this research of particular high value in the efforts to develop novel effective therapies against breast cancer, and possibly other solid tumors as well.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mitigation of Radiation Induced Gastrointestinal Syndrome.
  • 批准号:
    10706240
  • 项目类别:
  • 资助金额:
    $103.49万
  • 财政年份:
    2023
  • 负责人:
    Andrew John Norris
  • 依托单位:
A dual acting drug for enhancing radiotherapeutic benefit
  • 批准号:
    8648499
  • 项目类别:
  • 资助金额:
    $20.92万
  • 财政年份:
    2014
  • 负责人:
    Andrew John Norris
  • 依托单位:
海外基金